Jake Becraft

Jake Becraft, Co-founder and CEO of Strand Therapeutics, dives into the groundbreaking world of programmable mRNA therapies. He discusses how his team's innovative approach targets diseased cells, particularly in melanoma, turning the tide for patients once deemed incurable. Becraft reflects on the evolution of mRNA technology, its potential beyond vaccines, and the implications for future therapies like CAR-T and CRISPR. With insights on recent clinical trials and the surprising efficacy observed, he paints an exciting picture of synthetic biology's role in fighting cancer.